Morrama and Two Times Elliott have designed a refillable soap dispenser for Kankan. "The Kankan refillable soap dispenser is the perfect example of a less-is-more design approach," said Morrama.

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

This week’s quarterly results from Merck looked pretty good, all things considered: Sales and earnings came in ahead of Wall ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

LITESPARK-005 is part of Merck’s development program for Welireg comprised of four phase 3 trials in RCC, in which the company is evaluating Welireg in new combinations with other medicines ...

The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus ...

This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Merck, as a leading science and technology company, operates across healthcare, life sciences and performance materials. From advancing gene editing technologies and discovering unique ways to ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...